


RECEIVED
CENTRAL FAX CENTER

NOV 30 2006

Bristol-Myers Squibb Company
Patent Department

DATE: November 30, 2006

FACSIMILE TRANSMITTAL SHEET

TO: USPTO
FAX NO.: 571-273-8300
FROM: Mary K. VanAtten
TELEPHONE NO.: 609-252-4379
FACSIMILE NO.: 609-252-4526
RE: U.S. Application Serial No.: 10/785612
Our Docket No.: QA0283 / US - NP
Number of Pages: 4 (including cover sheet)

DETAILS OF TRANSMISSIONResponse to Restriction Requirement
One Month Extension of TimeCERTIFICATE OF TRANSMISSION VIA FACSIMILE

I hereby certify that the correspondence detailed above is being transmitted via facsimile to the U.S. Patent and Trademark Office, Fax number 571-273-8300 on November 30, 2006

Mary K. VanAtten
Telephone 609-252-4379

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU

NOV. 30. 2006 3:22PM

BMS PATENT DEPT

RECEIVED
CENTRAL FAX CENTER NO. 4816 P. 3

NOV 30 2006

QA0283 NP

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to 571-273-8300 to the Patent and Trademark Office on the date shown below.

Mary K. VanAthen
Type or print name

Mary VanAthen
Signature

November 30, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
YUPING QIU, ET AL
APPLICATION NO: 10/785612
FILED: 02/24/2004

ART UNIT: 1614
EXAMINER:

FOR: PYRAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND
PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action dated October 17, 2006, Applicants elect, with traverse, Group I, Claims 1 - 16, drawn to compounds and compositions. In response to the requirement to elect a single disclosed species, Applicants elect Example 16, page 58, as the species election. Claims 1-19 are readable thereon. However, Applicants understand this requirement for election of species is for initial examination purposes only, in accordance with MPEP §803.02, and not a requirement to restrict the scope of the generic and subgeneric claims of this application to such species. If the Office Action is a requirement to restrict the scope of the generic and subgeneric claims to the elected species, Applicants traverse this requirement. Such a requirement would be improper for the reasons stated in MPEP §803.02, first paragraph. Upon a finding of allowability of

QA0283 NP


the species, It is respectfully requested that the search be extended to the full extent of the invention as claimed. Applicant's further reserve the right to traverse any further restriction based on the species.

Rejoinder of the method of treating claims of Group II (claims 17-18) and Group III (claim 19) upon a finding of allowable compound claims of Group I is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is requested.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: November 30, 2006



Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408
Phone: 609-252-4379